Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $227K fell 7.0% year over year, behind the +7.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at +296.1% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.0% toward the trailing-twelve-month pace of +7.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.02M USD
- Year-over-year change
- +21.2%
- 3-year CAGR
- +296.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.02M | +21.2% |
| FY2024 | 2024-12-31 | 839K | +649.1% |
| FY2023 | 2023-12-31 | 112K | +584.4% |
| FY2022 | 2022-12-31 | 16.36K | — |
Depreciation & Amortization vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 depreciation & amortization of $1M is the 3rd largest of the 10 companies compared; the peer median is $328K.
- Its year-over-year change of +7.4% is the 4th highest of 9, against a peer median of -6.4%.
- Depreciation & amortization amounts to 5.0% of revenue for RAPP, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $12.02M | -12.0% | +79.7% | 1.1% | |
| LTM Jun 2026 | $9.94M | +16.8% | +27.2% | 1.3% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +296.1% | 5.0% |
| LTM Mar 2026 | $674K | +14.4% | +24.6% | — | |
| LTM Mar 2026 | $574K | -20.3% | +0.2% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $328K | +19.3% | -0.6% | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $251K | -0.8% | -1.0% | — | |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $328K | -6.4% | +0.2% | 1.2% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Depreciation & Amortization | 16.36K | 112K | 839K | 1.02M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 609.82K | 3.53M | 10.24M | 18.86M |
| Change in Working Capital | 1.49M | 2.65M | (2.42M) | 3.5M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 856K | (346K) | 2.22M |
| Other Working Capital | 1.49M | 1.8M | (2.07M) | 1.29M |
| Other Non-Cash Items | 5.3M | 1.32M | 4.82M | 636K |
| Operating Cash Flow | (3.24M) | (27.18M) | (64.83M) | (87.47M) |
| Capital Expenditures | (284K) | (1.64M) | (2.41M) | (616K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (77.22M) | (380.74M) | (354.78M) |
| Sales of Investments | 0 | 0 | 209.8M | 167.93M |
| Other Investing Activities | (5M) | 0 | 3.21M | 0 |
| Investing Cash Flow | (5.28M) | (78.86M) | (170.14M) | (187.47M) |
| Debt Repayment | 7.9M | 0 | 0 | 0 |
| Common Stock Issued | 31.79M | 54K | 157.71M | 270.79M |
| Common Stock Repurchased | 0 | (4K) | 0 | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (134K) | 7K | 0 |
| Financing Cash Flow | 39.69M | 145.14M | 221.63M | 270.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.16M | 39.1M | (13.34M) | (4.16M) |
| Free Cash Flow | (3.53M) | (28.82M) | (67.23M) | (88.09M) |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.